Permeabilisation of tumour margins in brain macrometastases using a type-1 receptor selective tumour necrosis factor mutein

Clicks: 11
ID: 328325
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #129 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Brain metastasis remains a major clinical challenge. The blood-brain barrier (BBB), which persists in the margins even in late-stage macrometastases, is a major impediment to effective drug delivery, surgery or radiotherapy. The aim of this study was to determine whether a mutein of human tumour necrosis factor (TNF) that is selective for the TNFR1 receptor could increase permeabilisation in the margins of brain metastases, enabling better delineation and more complete treatment. Methods Intracerebral xenograft mouse models of breast cancer (MDA231Br-GFP), melanoma (H1_DL2) and lung cancer (SEBTA) brain metastasis were used to test the efficacy of the TNF mutein (mutTNF) in permeabilising the margins of well-established macrometastases. Changes in tumour permeabilisation were assessed in vivo by gadolinium-enhanced magnetic resonance imaging (MRI) and ex vivo by IgG immunohistochemistry. Results Tumour margin permeabilisation was increased following mutTNF treatment in all three models. The MDA231Br-GFP model showed a significant increase in the extent of both gadolinium enhancement (P < 0.01) and IgG extravasation (P < 0.05), whilst significant effects were detected by MRI alone in the SEBTA (P < 0.01) and H1_DL2 (P < 0.05) models. Although a strong trend towards increased IgG extravasation was found in the SEBTA model (P = 0.076). Consistent with these findings, the models showed differing degrees of both infiltration and vascular TNFR1 expression at the margins (MDA231Br-GFP > SEBTA > H1_DL2), suggesting a greater sensitivity to mutTNF with increasing marginal invasiveness. Conclusions This work demonstrates the potential of TNFR1 selective mutTNF as an adjuvant strategy to improve tumour margin delineation and enhance therapeutic access in brain metastases.
Reference Key
openalex_W7212084615 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vanessa A. Johanssen, Claire Bristow, Sandra J. Campbell, Daniel C. Anthony, Mark R. Middleton, Nicola R. Sibson
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag239
URL
https://doi.org/10.1093/noajnl/vdag239
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.